Multicenter, Randomized Trial for Stage IIIB or IV Non–Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or Observation
BELANI, Chandra P, BARSTIS, John, PERRY, Michael C, LA ROCCA, Renato V, NATTAM, Sreenivasa R, RINALDI, David, CLARK, Ray, MILLS, Glenn M
Published in Journal of clinical oncology (01.08.2003)
Published in Journal of clinical oncology (01.08.2003)
Get full text
Journal Article
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Catenacci, Daniel V T, Junttila, Melissa R, Karrison, Theodore, Bahary, Nathan, Horiba, Margit N, Nattam, Sreenivasa R, Marsh, Robert, Wallace, James, Kozloff, Mark, Rajdev, Lakshmi, Cohen, Deirdre, Wade, James, Sleckman, Bethany, Lenz, Heinz-Josef, Stiff, Patrick, Kumar, Pankaj, Xu, Peng, Henderson, Les, Takebe, Naoko, Salgia, Ravi, Wang, Xi, Stadler, Walter M, de Sauvage, Frederic J, Kindler, Hedy L
Published in Journal of clinical oncology (20.12.2015)
Published in Journal of clinical oncology (20.12.2015)
Get full text
Journal Article
Treatment of Elderly Non–small Cell Lung Cancer Patients with Three Different Schedules of Weekly Paclitaxel in Combination with Carboplatin: Subanalysis of a Randomized Trial
Ramalingam, Suresh, Barstis, John, Perry, Michael C., La Rocca, Renato V., Nattam, Sreenivasa R., Rinaldi, David, Clark, Ray, Mills, Glenn M., Belani, Chandra P.
Published in Journal of thoracic oncology (01.03.2006)
Published in Journal of thoracic oncology (01.03.2006)
Get full text
Journal Article
Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202
Ruppert, Amy S., Mandrekar, Sumithra J., Booth, Allison M., Ding, Wei, Bartlett, Nancy L., Brander, Danielle M., Coutre, Steve E., Brown, Jennifer R., Nattam, Sreenivasa R., Larson, Richard A., Erba, Harry Paul, Litzow, Mark Robert, Owen, Carolyn, Kuzma, Charles S., Abramson, Jeremy S., Little, Richard F., Smith, Scott E., Stone, Richard M., Byrd, John C., Woyach, Jennifer Ann
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer
Liu, Joyce F., Barry, William Thomas, Birrer, Michael J., Lee, Jung-min, Buckanovich, Ronald J., Fleming, Gini F., Rimel, Bj, Buss, Mary K., Nattam, Sreenivasa R., Hurteau, Jean, Luo, Weixiu, Farooq, Sarah, Whalen, Christin, Kohn, Elise C., Ivy, S. Percy, Matulonis, Ursula A.
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article
A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer
Liu, Joyce, Barry, William Thomas, Birrer, Michael J., Lee, Jung-min, Buckanovich, Ronald J., Fleming, Gini F., Rimel, Bj, Buss, Mary K., Nattam, Sreenivasa R., Hurteau, Jean, Luo, Weixiu, Quy, Philippa, Obermayer, Elizabeth, Whalen, Christin, Lee, Hang, Winer, Eric P., Kohn, Elise C., Ivy, S. Percy, Matulonis, Ursula
Published in Journal of clinical oncology (20.06.2014)
Published in Journal of clinical oncology (20.06.2014)
Get full text
Journal Article
A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer
Liu, Joyce, Barry, William Thomas, Birrer, Michael J., Lee, Jung-min, Buckanovich, Ronald J., Fleming, Gini F., Rimel, Bj, Buss, Mary K., Nattam, Sreenivasa R., Hurteau, Jean, Luo, Weixiu, Quy, Philippa, Obermayer, Elizabeth, Whalen, Christin, Lee, Hang, Winer, Eric P., Kohn, Elise C., Ivy, S. Percy, Matulonis, Ursula
Published in Journal of clinical oncology (20.05.2014)
Published in Journal of clinical oncology (20.05.2014)
Get full text
Journal Article
Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study
Catenacci, Daniel Virgil Thomas, Bahary, Nathan, Nattam, Sreenivasa R., Marsh, Robert de Wilton, Wallace, James Alfred, Rajdev, Lakshmi, Cohen, Deirdre Jill, Sleckman, Bethany G., Lenz, Heinz-Josef, Stiff, Patrick J., Thomas, Sachdev P., Xu, Peng, Henderson, Les, Horiba, Margit Naomi, Vannier, Michael, Karrison, Theodore, Stadler, Walter Michael, Kindler, Hedy Lee
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study
Catenacci, Daniel Virgil Thomas, Bahary, Nathan, Edelman, Martin J., Nattam, Sreenivasa R., Marsh, Robert de Wilton, Kaubisch, Andreas, Wallace, James Alfred, Cohen, Deirdre Jill, Stiff, Patrick J., Sleckman, Bethany G., Thomas, Sachdev P., Lenz, Heinz-Josef, Henderson, Les, Zagaya, Ciara, Vannier, Michael, Karrison, Theodore, Stadler, Walter Michael, Kindler, Hedy Lee
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article